Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published September 2014
  • Article
  • Info & Metrics
  • PDF
Loading

CDK4/6 Inhibitor NVP-LEE011 in Liposarcoma

Zhang et al. Page 2184

The cyclin-dependent kinase 4 (CDK4) gene is highly amplified in over 95% of well-differentiated/dedifferentiated liposarcomas (WD/DDLPS). Here, Zhang and colleagues explored the effects of NVP-LEE011, a novel selective inhibitor of CDK4/6, on a panel of human liposarcoma cell lines in vitro and patient-derived tumor xenografts in vivo. NVP-LEE011 induced retinoblastoma protein-dependent cell-cycle arrest, and decreased cell proliferation as well as tumor glucose metabolism, which resulted in tumor growth inhibition or regression. These findings validate the critical role of CDK4 in the growth of liposarcoma and suggest the potential application of its inhibitor, NVP-LEE011, in liposarcoma treatment.

Optimizing the Combination of Taxanes and MLN8237

Huck et al. Page 2170

MLN8237 (alisertib) is a selective Aurora A inhibitor that displays additive and synergistic antitumor activity in combination with taxanes in preclinical models of breast cancer. An exposure–efficacy model was generated with the preclinical combination of MLN8237 and paclitaxel. Exposures of both agents achieved in patients were mapped onto the model to predict which combination of exposures would lead to the greatest antitumor activity based on clinically feasible doses. This model was used as a factor in selecting the phase 2 dose for these agents in cancer patients. Similar approaches can guide dose-schedule optimization for combinations of other therapeutic agents.

Combination of Quinacrine and Erlotinib in NSCLC

Dermawan et al. Page 2203

The effect of erlotinib remains modest in non–small cell lung cancer (NSCLC) patients with wild-type (wt) epidermal growth factor receptor (EGFR). To improve the efficacy of erlotinib, Dermawan and colleagues tested the combination of erlotinib with quinacrine, which inhibits the FACT (facilitates chromatin transcription) complex required for NF-κB activity. This drug combination showed highly synergistic effect in three representative NSCLC cell lines resistant to anti-EGFR therapy. Moreover, genes that were strongly suppressed by the combination in NSCLC cells predicted the poor survival in lung adenocarcinoma patients. This experimental evidence provides the basis for testing this novel combination in clinical trial.

  • ©2014 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 13 (9)
September 2014
Volume 13, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther September 1 2014 (13) (9) 2139;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther September 1 2014 (13) (9) 2139;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • CDK4/6 Inhibitor NVP-LEE011 in Liposarcoma
    • Optimizing the Combination of Taxanes and MLN8237
    • Combination of Quinacrine and Erlotinib in NSCLC
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement